Compare Amplify Transformational Data Sharing ETF (BLOK) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs CVS Health Corp — how do they compare? Amplify Transformational Data Sharing ETF trades at $60.34, while CVS Health Corp trades at $94.08 (market cap $119.58B). The key difference: CVS Health Corp pays a 2.84% dividend while Amplify Transformational Data Sharing ETF pays none, and CVS Health Corp is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | CVS | |
|---|---|---|
52-Week High | $74.10 | $110.60 |
52-Week Low | $47.36 | $65.51 |
Market Cap | — | $119.58B |
Sector | — | Health |
Enterprise Value | — | $181.93B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.12, up 1.76% with a bearish technical signal from moving averages but neutral oscillators. Support lies at $59 and resistance at $61. The ETF's financial ratios are not disclosed, and a small dividend of $0.08 is scheduled for June 2026. Recent news highlights institutional trimming and focus on AI infrastructure holdings.
Outlook remains cautious due to bearish technicals and lack of fundamental data. Risks include sector volatility and institutional selling. Opportunities may arise from AI-driven growth in portfolio companies, but investors should await clearer financial metrics for valuation.
CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.
The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
